1. Introduction {#sec1}
===============

B lymphocytes produce immunoglobulins consisting of a heavy chain and either a kappa (*IGKC*) or a lambda (*IGLC*) light chain. Each B lymphocyte decides early by the rearrangement of its immunoglobulin genes which light chain to produce \[[@B1]\]. The excluded light chain gene is not properly rearranged or remains in germ line configuration \[[@B2]\]. In healthy humans 60--70% of the B cells produce kappa chains and the rest produce lambda chains \[[@B1], [@B3]\]. Normal lymphoid tissues therefore contain a mixture of B cells that express *IGKC* and *IGLC* at a ratio of about 60 : 40 = 1.5.

Tumors of B cell origin are monoclonal and arise from one transformed cell. The single cell origin of malignant clones results in exclusive expression of *IGKC* or *IGLC* light chains in the vast majority of all B cell malignancies although B cell tumors that produce both kappa and lambda chains have been reported \[[@B4]\]. The clonal expression of *IGKC* or *IGLC* is thus used as an important diagnostic marker for B cell malignancies and currently determined on protein level by immunohistochemistry (IHC), flow cytometry (FC), or enzyme-linked immunosorbent assay techniques. Previously, we used reverse transcription quantitative real-time PCR (RT-qPCR) to quantify *IGKC* and *IGLC* gene transcripts in a small set of lymphomas and found that also gene expression level clonality was frequently evident \[[@B5]\]. In the present study we have used the same RT-qPCR method together with IHC and FC to analyze a larger cohort of 39 non-Hodgkin lymphomas, 16 chronic lymphatic leukemias, and 5 B cell derived tumor cell lines. The non-Hodgkin lymphomas consisted of 20 diffuse large B cell lymphomas, 16 follicular lymphomas, and 3 mantle cell lymphomas.

2. Material and Methods {#sec2}
=======================

2.1. Biopsies, Flow Cytometry, and Immunohistochemistry {#sec2.1}
-------------------------------------------------------

The samples were transported from the operation theatre in ice-water-chilled boxes, handled in the laboratory within 30 min, and stored at −140°C. Parts of the tissues were fixed in formalin and embedded in paraffin according to the routine protocols of the pathology laboratory. Diagnosis was reached by a combination of microscopic histological evaluation, IHC of several markers, including the *κ* and *λ* chains, and in some cases by FC. Series of 5 *μ*m tissue sections were cut from each biopsy, deparaffinized, rehydrated, and stained with the following antibodies: rabbit anti-human kappa light chains and rabbit anti-human lambda chains (A0191 and A0194, DAKO). The antibodies were used at a dilution of 1 : 400 and bound antibodies were visualized using the second labeled antibody streptavidin biotin peroxidase system (DAKO). Stained sections were examined with a light microscope. For FC, a routine protocol for preparation of lymphoid cells from lymphoma tissue was used. Direct labeled antibodies specific for immunoglobulin kappa and lambda chains (A0191 and A0194, DAKO) were used for staining of recovered cells. First a gate for lymphocytes was set using forward and side scatter, followed by gates for kappa and lambda staining cells. We used a kappa : lambda ratio less than 0.4 or greater than 5 to prove FC monoclonality \[[@B6]\]. The samples were classified according to the Revised European-American Lymphoma and World Health Organization classification system.

2.2. RNA Extraction and RT-qPCR {#sec2.2}
-------------------------------

RNA was extracted by use of the Fast Prep System (FastRNA Green; Qbiogene). We mixed 10 *μ*g of total RNA with 2 *μ*g of poly (dT) oligomers (Pharmacia) and incubated the mixture at 65°C for 5 min. First-strand cDNA synthesis was performed by adding 0.05 mol/L Tris-HCl (pH 8.3), 0.075 mol/L KCl, 3 mmol/L MgCl~2~, 0.01 mol/L dithiothreitol, 10 U/mL Moloney murine leukemia virus reverse transcriptase (Life Technologies), 0.05 units/mL RNA guard (Life Technologies), and 10 mmol/L of each deoxyribonucleotide (Life Technologies) to a final volume of 20 *μ*L and incubating the samples at 37°C for 1 h. The reaction was terminated by incubation at 65°C for 5 min, and samples were stored at −80°C. Real-time PCR measurements were performed on a Rotorgene 3000 (Corbett Research). Each PCR reaction contained 10 mmol/L Tris-HCl pH 8.3, 50 mmol/L KCl, 4 mM MgCl~2~, 400 *μ*mol/L each dNTP, 300 nmol/L each primer, 0.04 U/*μ*L Jumpstart Taq (Sigma), and 0.25x SYBR Green (Molecular Probes) in a 20 *μ*L reaction volume. The temperature profile was 95°C for 3 min followed by 40 cycles of amplification (95°C for 20 sec, 60°C for 20 sec, and 72°C for 20 sec). Primer sequences and detailed assay performance for *IGKC* and *IGLC* are reported elsewhere \[[@B5]\]. Formation of correctly sized PCR products was confirmed by agarose gel electrophoresis for all assays and melting curve analysis for all samples. RT-qPCR and statistical analysis of the data were performed as previously described \[[@B5]\]. A 95% confidence region for the *IGKC* : *IGLC*ratio using the negative lymphadenitis was used to prove RT-qPCR monoclonality.

2.3. RT-PCR Cloning and Sequencing {#sec2.3}
----------------------------------

PCR products were obtained as for QPCR analysis and fractionated by agarose electrophoresis. Fragments were excised from the gels and used as templates for DNA sequencing as previously described \[[@B7]\].

3. Results and Discussion {#sec3}
=========================

The samples were analyzed by IHC, FC, and RT-qPCR for expression of IGKC and IGLC light chains (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}). IHC indicated an exclusive or heavily dominant expression of IGKC or IGLC chains indicative of a monoclonal origin in all but one analyzed samples (98%). RT-qPCR analysis indicated a monoclonal dominance in 33 of 55 (60%) analyzed samples, while FC scored monoclonal dominance in 30 of 39 (77%) analyzed samples. Thus the IHC method was superior to FC and RT-qPCR in detecting monoclonality. The divergent results may in part be explained by the fact that biopsies, besides the tumor cells, often contain considerable numbers of normal lymphocytes that could contribute to the RNA samples analyzed by RT-qPCR and the cell population studied by flow cytometry. IHC analysis, on the other hand, allows for selective analysis of representative parts of the tumor tissue thus avoiding contribution of normal B lymphocytes. Furthermore, it is also known that 60--70% of non-Hodgkin lymphomas lack surface expression of IGLK and IGLC \[[@B8]\].

FC was more efficient than RT-qPCR in identifying clonal populations. However, there was an overall good correlation in expression levels of *IGKC* and *IGLC* between FC and RT-qPCR data despite the fact that FC data reflects cell number and RT-qPCR data reflects transcript numbers ([Figure 1](#fig1){ref-type="fig"}). In two cases (samples 135 and 168, [Table 1](#tab1){ref-type="table"}), RT-qPCR detected clonal populations where FC failed. RT-qPCR may therefore serve as a valuable complement to IHC and FC in detection of monoclonal B cell populations. Moreover, RT-qPCR analysis can also be employed on minute fine needle aspirate samples that are not sufficient for flow cytometry or IHC and the same sample may also be analyzed simultaneously for expression of more marker genes.

Several of the *IGKC* and *IGLC* cotranscribing tumors appeared by IHC and FC to consist of homogenous tumor cell populations with no or few normal lymphocytes suggesting that some malignant B cell clones were dual producers of light chain mRNA ([Figure 2](#fig2){ref-type="fig"}). Dual production of *IGLC* chain mRNAs and proteins has been reported for various types of malignant B cell clones and normal B lymphocytes \[[@B4], [@B9]\]. These reports and our data prompted us to analyze five monoclonal B cell derived tumor cell lines ([Table 3](#tab3){ref-type="table"}). These cell lines produce only one light chain species as analyzed by immunofluorescence, but four of them contained both *IGKC* and *IGLC* transcripts. To further confirm this result we isolated PCR products from two of the cell lines and sequence analysis showed that *IGKC* and *IGLC* transcripts were indeed produced simultaneously in these cell lines. Thus we conclude that human monoclonal B-lymphoid populations frequently simultaneously produce *IGKC* and *IGLC* transcripts.

We searched for possible correlations between dual light chain producers and tumor type. Dual producers were most common in the follicular lymphoma group in which 11/16 tumors failed to score for monoclonality based on RT-qPCR analysis. This could possibly be explained by larger abundance of normal cells in follicular lymphomas since FC showed highest failure rate for these samples, and may also depend on a higher frequency of dual producers.

Eleven of twelve cases where monoclonality was not detected by RT-qPCR produced IGKC protein as judged by IHC. This is more than expected from the normal ratio of IGKC and IGLC producers among normal B lymphocytes and lymphoma populations. In the present cohort of IHC investigated lymphomas, 30% were lambda producers. Thus, it is possible that dual mRNA producers arise more often among kappa protein producing cells. This is surprising since kappa chains are considered to be rearranged first and *IGLC* rearrangement is pursued only if *IGKC* rearrangement fails to produce a functional IGKC protein \[[@B10]\]. The activation of *IGLC* transcription is most likely a result of rearrangement that occurs after IGKC protein is produced and may therefore indicate a failure to inactivate the rearrangement mechanism. Failure to regulate a potentially risky DNA rearrangement process may also contribute to the frequent multiple genetic rearrangements in lymphomas. Age and gender were not correlated to the determined clonality (data not shown).

4. Conclusions {#sec4}
==============

We conclude that IHC, FC, and RT-qPCR analysis of human B-lymphoid tumors gives partially divergent results. This may in part be explained by contribution of normal B lymphocytes into the tumor tissue. Our results also suggest that dual transcription of *IGKC* and *IGLC* loci is common in these tumors. This has to be taken in consideration when RT-qPCR analysis of *IGKC* and *IGLC* is used for diagnostic purpose. RT-qPCR remains an interesting complement for diagnostic purpose when only small samples, such as from fine needle cytology, are available.
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![Comparison of IGKC : IGLC ratio between FC and RT-qPCR. The Pearson correlation coefficient is 0.65 (*P* \< 0.01). The FC ratio refers to cell number, while the RT-qPCR ratio refers to transcript number. The areas where no monoclonality (MNP) could be proven are shown as dashed lines. Grey square, lymphadenitis; stars, diffuse large B cell lymphoma; triangles, chronic lymphocytic leukemia; dot, follicular lymphoma; circles, mantle cell lymphoma; *κ*, IGKC; *λ*, IGLC.](ISRN.ONCOLOGY2014-796210.001){#fig1}

![Immunohistochemistry of sample 165. The follicular lymphoma sample 165 was stained for (a) IGKC and (b) IGLC. Using RT-qPCR no clonality could be proven for this IGKC IHC positive sample.](ISRN.ONCOLOGY2014-796210.002){#fig2}

###### 

Detailed patient information.

  Sample ID   Classification   Gender   Age   FC       IHC      RT-qPCR
  ----------- ---------------- -------- ----- -------- -------- ---------
  111         CLL              F        70    ND       Lambda   Lambda
  112         CLL              F        82    ND       Lambda   MNP
  113         CLL              M        58    Lambda   Lambda   Lambda
  115         CLL              F        61    Lambda   Lambda   Lambda
  116         CLL              F        57    Kappa    Kappa    Kappa
  117         CLL              F        75    Kappa    Kappa    Kappa
  118         CLL              F        85    Kappa    Kappa    Kappa
  119         CLL              F        48    ND       Lambda   Lambda
  131         CLL              M        72    ND       Lambda   Lambda
  132         CLL              F        59    ND       Lambda   Lambda
  145         CLL              F        76    Kappa    Kappa    MNP
  146         CLL              M        46    Lambda   Lambda   Lambda
  147         CLL              F        74    Kappa    Kappa    Kappa
  149         CLL              F        76    Kappa    Kappa    MNP
  189         CLL              F        65    Kappa    Kappa    MNP
  191         CLL              M        60    Lambda   Lambda   Lambda
  120         DLBL             M        80    ND       Kappa    MNP
  121         DLBL             M        81    ND       Kappa    Kappa
  123         DLBL             M        64    Kappa    Kappa    Kappa
  124         DLBL             F        77    Kappa    Kappa    Kappa
  125         DLBL             M        57    ND       MNP      Lambda
  126         DLBL             M        70    Lambda   Lambda   Lambda
  127         DLBL             M        70    Kappa    Kappa    Kappa
  129         DLBL             M        58    ND       Kappa    MNP
  133         DLBL             M        72    MNP      Lambda   MNP
  135         DLBL             F        75    MNP      Kappa    Kappa
  136         DLBL             F        78    ND       Kappa    MNP
  137         DLBL             M        70    Kappa    Kappa    Kappa
  138         DLBL             M        72    ND       Kappa    MNP
  139         DLBL             M        33    Kappa    Kappa    Kappa
  140         DLBL             F        78    Kappa    Kappa    kappa
  153         DLBL             M        19    ND       Kappa    Kappa
  156         DLBL             M        58    Kappa    Kappa    Kappa
  182         DLBL             F        75    MNP      Kappa    MNP
  184         DLBL             M        55    Kappa    Kappa    Kappa
  186         DLBL             F        66    Kappa    Kappa    Kappa
  157         FL               F        54    Kappa    Kappa    MNP
  158         FL               F        51    ND       Kappa    MNP
  159         FL               M        77    ND       Kappa    MNP
  160         FL               F        60    ND       Lambda   MNP
  161         FL               M        70    Lambda   Lambda   MNP
  162         FL               M        69    Kappa    Kappa    Kappa
  163         FL               M        52    Kappa    Kappa    Kappa
  164         FL               M        53    ND       Kappa    Kappa
  165         FL               F        59    Kappa    Kappa    MNP
  166         FL               M        61    MNP      Kappa    MNP
  167         FL               F        30    MNP      Lambda   MNP
  168         FL               M        51    MNP      Kappa    Kappa
  208         FL               F        83    MNP      ND       MNP
  209         FL               F        55    Lambda   Lambda   Lambda
  210         FL               F        46    MNP      Kappa    MNP
  211         FL               M        64    Lambda   ND       MNP
  204         MCL              M        61    Lambda   Lambda   Lambda
  206         MCL              F        78    Kappa    Kappa    Kappa
  207         MCL              F        70    Kappa    Kappa    MNP
  101         LA               F        62    ND       MNP      Control
  102         LA               M        25    ND       MNP      Control
  103         LA               M        25    ND       MNP      Control
  104         LA               M        16    ND       MNP      Control
  105         LA               F        58    ND       MNP      Control
  106         LA               M        59    ND       MNP      Control
  107         LA               M        41    ND       MNP      Control
  108         LA               M        7     ND       MNP      Control
  109         LA               F        33    ND       MNP      Control
  110         LA               F        28    ND       MNP      Control
  192         LA               F        1     MNP      MNP      Control
  193         LA               F        40    MNP      MNP      Control
  194         LA               M        28    MNP      MNP      Control
  195         LA               M        20    MNP      MNP      Control
  196         LA               M        13    MNP      MNP      Control
  197         LA               M        30    MNP      MNP      Control
  198         LA               F        10    MNP      MNP      Control
  199         LA               F        58    MNP      MNP      Control
  200         LA               M        49    MNP      MNP      Control
  201         LA               F        57    MNP      MNP      Control

CLL: chronic lymphocytic leukemia; DLBL: diffuse large B cell lymphoma; FL: follicular lymphoma; LA: lymphadenitis; F: female; M: male; MNP: monoclonality not proven; FC: flow cytometry; IHC: immunohistochemistry.

###### 

Monoclonal populations detected in lymphoma and lymphadenitis biopsies^a^.

                       RT-qPCR   FC      IHC
  -------------------- --------- ------- -------
  CLL                  12/16     11/11   16/16
  DLBL                 14/20     10/13   19/20
  FL                   5/16      6/12    14/14
  MCL                  2/3       3/3     3/3
  CLL/lymphoma total   33/55     30/39   52/53
  LA                   0/20      0/10    0/20

^a^Number of samples with clonality proven/total number of samples is shown. CLL: chronic lymphocytic leukemia; DLBL: diffuse large B cell lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; LA: lymphadenitis (polyclonal control).

###### 

RT-qPCR data for 5 B-lymphoid tumor cell lines.

  Cellinje       Kappa Cq   Lambda Cq   Kappa noRT Cq   Lambda noRT Cq   mRNA expression       IHC
  -------------- ---------- ----------- --------------- ---------------- --------------------- --------
  U698           10.3       13.8        27              23.5             Kappa \> Lambda       Kappa
  DG75           10.4       15.9        25.2            24.2             Kappa \> Lambda       Kappa
  MC116          34.8       10.4        Not detected    23.5             Lambda only           Lambda
  RPMI8226       12.2       14.4        25.1            22.2             Kappa \> Lambda       Lambda
  CCRF-SB        12.3       11.2        26.7            24.4             Lambda \</*≈* Kappa   Kappa
  Neg. control   \>33       \~30                                                                

Cq: cycle of quantification (log transcript numbers); noRT: samples without reverse transcriptase; IHC: immunohistochemistry.
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